Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Xcite, ReNeuron, CPL Resources

Thu, 28th Jan 2010 11:25

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea.ReNeuron group climbed after the stem cell developer said Phase 1 trials for its ReN001 stroke treatment should be given the green light soon following a favourable response to data provided to the UK Gene Therapy Advisory Committee.Irish recruitment group CPL Resources tumbled Thursday as it reported a big drop in gross profit and much lower revenue for the six months to 31 December.Gross profit fell 37% to €13m and profit before tax and an impairment charge of €4.5m in 2008 slumped to €2.4m from €6m. Revenue sank to €91.4m from €118.9m.Publishing Technology, which provides software and services to the publishing industry, says delays to project spend in both the UK and US because of the recession mean revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) will be unchanged from the year before.But earnings before tax are expected to be 'significantly' better as 2009 contains no further amortisation of intangible assets or provisions for onerous leases.Product development software specialist Sopheon predicts revenues for the year ended 31 December 2009 will exceed £8m, although that's down from £9.3m in 2008.Chairman Barry Mence says a profitable fourth quarter shows that 'we reacted appropriately to balancing investment with cost containment'. 'Our current pipeline, coupled with our unique solution set and the continued maturing of our chosen market, gives me continued confidence in our quest to improve shareholder value.'Internet booth and WiFi hotspot provider Spectrum Interactive has completed the roll-out of WiFi services across the motorway service station estate of Moto Hospitality. 'This is an important contract for Spectrum, as it is first to bring Spectrum's WiFi service to the UK motorway services sector.Film finance provider and movie promoter Intandem has made a 'positive start' to 2010. It has completed one film, "The Kid", which it expects to show at the Berlin Flim Festival in February, and has four more films in post-production, all of which should be ready for the Cannes film festival.The s still in advanced negotiations to settle the £5.7m loan and expects to make a further announcement in due course.Asia-focused online advertising sales company Pixel Interactive is to lose a customer that provided a substantial proportion of its turnover in 2009. The company is in negotiations with the customer to minimise the impact on Pixel, but the change is likely to have a material impact on Pixel's revenue and profit forecasts for 2010.Online tech retailer Expansys cut losses sharply in the six months to October to just £162,000 against £1.73m. Revenues for the period were £20.4m (2008: £25.3m), but fell 6% on the six months to 30 April 2009. Pre-tax losses were £24,000 (2008: £1.1m). Chief executive Roger Butterworth has stepped down to pursue other business opportunities.Electronic displays group Densitron returned to profitability in the second half of 2009 and expects to return a small profit for the year as a whole.Advanced Medical Solutions says Cardinal Health, a major US healthcare services company, is marketing and distributing AMS's LiquiBand topical skin adhesive range in the US to hospitals, care centres, and surgeries.Hansard Global reports new business in Q2 2009/10 was 25% ahead of Q1 at £40.9m. The group had $1.16bn of Assets under Administration at 31 December 2009, up 15.6% since 30 June 2009. Policyholder cash flows have been strong through the period;
More News
12 Jul 2010 07:27

ReNeuron Group To Present New Data Of Lead CTX Stem Cell Line

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN), a clinical-stage stem cell business, said Monday it will present important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. MAIN FACTS: -The results of these studies will be pr

Read more
29 Jun 2010 07:51

ReNeuron Group FY Pretax Loss GBP6.2M On Revenue GBP31,000

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GB

Read more
28 Jan 2010 13:48

Sector movers: Drug sector off colour

The pharmaceuticals sector fell back after AstraZeneca posted a 10% rise in fourth quarter earnings, but predicted 2010 revenues would be hit by the loss of exclusive rights to sell certain drugs. The company is also planning to cut 8,000 jobs from its global workforce of 63,000. While Astra falls

Read more
11 Jan 2010 16:41

London close: Footsie gives up gains

The leading share index gave up early gains to finish only slightly higher as euphoria over strong trade figures from China in December gave way to renewed fears over recovery prospects. China's December imports jumped by 55.9% from the same month the previous year, while exports were 17.7% higher

Read more
11 Jan 2010 14:16

London afternoon: Stocks back on the climb

Leading shares, which had been surrendering early gains at the end of the morning, picked up again over the lunch time session, helped by expectations of a firm start by Wall Street. In the absence of much in the way of corporate events to attract attention, traders have been focused on broker note

Read more
11 Jan 2010 08:44

ReNeuron poised for stroke treatment trials

Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year. ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is r

Read more
26 Nov 2009 14:45

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m. "Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a

Read more
16 Nov 2009 11:54

Small caps round-up: Ocean Wilsons, Fortune Oil, Freshwater...

PR and marketing group Freshwater's profits fell sharply last year, but the fourth quarter saw an improvement that has continued into the current year. Pre-tax profit fell to £0.24m from £1.17m, on sales of £9.1m down from £9.5m. "Profitability improved in the second half, and we have gone into th

Read more
2 Oct 2009 15:33

ReNeuron boosted by study findings

Shares in stem cell developer ReNeuron were wanted after the company drew attention to the publication of new research using the company's ReNcell neural stem cell products. Researchers based in California have developed a safe strategy for reprogramming cells to a pluripotent (capable of affecting

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
8 Jul 2009 13:44

Sector movers: Astra lifts drug stocks after broker boost

Pharmaceutical stocks are higher after the broker Panmure Gordon said AstraZeneca was set to benefit from US rivals that produce generic alternatives to its cancer drug Casodex being too slow off the mark. AstraZeneca's slight rise is not as impressive as that of stem cell therapy developer ReNeuro

Read more
8 Jul 2009 10:55

Small caps round-up: Brainjuicer, ReNeuron, Hamworthy...

Market researcher BrainJuicer, whose clients include Unilever and Nike, posted revenue growth of about 22% for the first half and said it expects to make further progress in 2009. Stem cell therapy developer ReNeuron said clinical data on its lead CTX neural stem cell line in stroke and neurodegene

Read more
30 Jun 2009 09:00

Small caps round-up: MediaZest, Reneuron, Atlantic Coal...

Display advertising and screens provider Mediazest's pre-tax profits slide in the year as administrative expenses were too high, prompting the firm to undertake further cost cutting measures. The group also said first half of 2009 has seen a drop in activity as a consequence of the economic downt

Read more
9 Jun 2009 12:21

Angel rallies on ReNeuron deal

Angel Biotechnology rallied on news that the biopharmaceutical contract manufacturer signed a GMP manufacturing deal with ReNeuron. The value of the contract was not disclosed. The signing of deal follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.